Morgan Stanley
BBC icon

Morgan Stanley’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Morgan Stanley’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$634K Sell
15,236
-1,623
-10% -$66.5K ﹤0.01% 5370
2025
Q4 		$650K Buy
16,859
+6,119
+57% +$208K ﹤0.01% 5383
2025
Q3 		$293K Buy
10,740
+2,285
+27% +$52.1K ﹤0.01% 5734
2025
Q2 		$163K Buy
8,455
+11
+0.1% +$200 ﹤0.01% 5929
2025
Q1 		$148K Sell
8,444
-3,053
-27% -$65.5K ﹤0.01% 5851
2024
Q4 		$275K Sell
11,497
-1,656
-13% -$45.7K ﹤0.01% 5668
2024
Q3 		$368K Sell
13,153
-8,146
-38% -$225K ﹤0.01% 5535
2024
Q2 		$538K Sell
21,299
-18,991
-47% -$507K ﹤0.01% 5261
2024
Q1 		$1.17M Buy
40,290
+22,068
+121% +$605K ﹤0.01% 4875
2023
Q4 		$446K Buy
18,222
+11,706
+180% +$231K ﹤0.01% 5667
2023
Q3 		$128K Buy
6,516
+1,744
+37% +$38.7K ﹤0.01% 5767
2023
Q2 		$114K Sell
4,772
-840
-15% -$20.2K ﹤0.01% 5888
2023
Q1 		$123K Sell
5,612
-800
-12% -$20.1K ﹤0.01% 5931
2022
Q4 		$160K Sell
6,412
-465
-7% -$11.6K ﹤0.01% 5760
2022
Q3 		$169K Sell
6,877
-96
-1% -$2.45K ﹤0.01% 5807
2022
Q2 		$151K Buy
6,973
+251
+4% +$5.52K ﹤0.01% 6028
2022
Q1 		$188K Sell
6,722
-799
-11% -$23.6K ﹤0.01% 5958
2021
Q4 		$290K Buy
7,521
+703
+10% +$30K ﹤0.01% 5866
2021
Q3 		$312K Sell
6,818
-6,953
-50% -$325K ﹤0.01% 5758
2021
Q2 		$688K Buy
13,771
+1,047
+8% +$51.2K ﹤0.01% 5316
2021
Q1 		$654K Buy
12,724
+2,023
+19% +$111K ﹤0.01% 4998
2020
Q4 		$531K Sell
10,701
-3,571
-25% -$160K ﹤0.01% 5046
2020
Q3 		$556K Sell
14,272
-17,279
-55% -$704K ﹤0.01% 4583
2020
Q2 		$1.36M Buy
31,551
+12,587
+66% +$482K ﹤0.01% 3929
2020
Q1 		$556K Buy
18,964
+5,602
+42% +$193K ﹤0.01% 4316
2019
Q4 		$508K Buy
13,362
+4,361
+48% +$130K ﹤0.01% 4916
2019
Q3 		$214K Buy
9,001
+1,480
+20% +$40.2K ﹤0.01% 5091
2019
Q2 		$217K Buy
7,521
+2,372
+46% +$66.2K ﹤0.01% 4989
2019
Q1 		$147K Buy
5,149
+103
+2% +$2.7K ﹤0.01% 5215
2018
Q4 		$117K Sell
5,046
-5,283
-51% -$144K ﹤0.01% 5492
2018
Q3 		$357K Sell
10,329
-6,586
-39% -$222K ﹤0.01% 5177
2018
Q2 		$553K Buy
16,915
+14,207
+525% +$467K ﹤0.01% 5033
2018
Q1 		$89K Buy
2,708
+1,308
+93% +$42.7K ﹤0.01% 5736
2017
Q4 		$40K Hold
1,400
– – ﹤0.01% 5881
2017
Q3 		$41K Hold
1,400
– – ﹤0.01% 5838
2017
Q2 		$34K Sell
1,400
-35
-2% -$784 ﹤0.01% 5954
2017
Q1 		$34K Sell
1,435
-65
-4% -$1.38K ﹤0.01% 5938
2016
Q4 		$28K Sell
1,500
-2,470
-62% -$49.3K ﹤0.01% 5907
2016
Q3 		$90K Buy
3,970
+2,600
+190% +$53.3K ﹤0.01% 5351
2016
Q2 		$25K Hold
1,370
– – ﹤0.01% 5772
2016
Q1 		$26K Sell
1,370
-400
-23% -$7.76K ﹤0.01% 5838
2015
Q4 		$51K Buy
1,770
+400
+29% +$11.6K ﹤0.01% 5707
2015
Q3 		$36K Buy
1,370
+1,300
+1,857% +$44K ﹤0.01% 5845
2015
Q2 		$3K Sell
70
-100
-59% -$3.44K ﹤0.01% 6466
2015
Q1 		$5K Buy
+170
New +$5.19K ﹤0.01% 6333

Other funds holding BBC

KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $454M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
APW
Aurora Private Wealth Rockaway, New Jersey $158M AUM
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
GAA
Global Assets Advisory Orlando, Florida $458M AUM 29.73% 1-Year Est. Return

Morgan Stanley's BBC Position: Q1 2026 in Review

Morgan Stanley reduced its Virtus Biotech Clinical Trials ETF (BBC) stake by 9.6% in Q1 2026, selling an estimated $66.5K and leaving 15,236 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #5370.

Morgan Stanley first reported a position in BBC in Q1 2015 and has held it in 45 quarters since. The position peaked at $1.36M in Q2 2020. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

  • Morgan Stanley held 15,236 shares of Virtus Biotech Clinical Trials ETF worth $634K as of Q1 2026.
  • Morgan Stanley sold 1,623 Virtus Biotech Clinical Trials ETF shares in Q1 2026, an estimated $66.5K.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5370 holding.
  • Morgan Stanley first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2015 and has held it in 45 quarters since.
  • Morgan Stanley's Virtus Biotech Clinical Trials ETF position peaked at $1.36M in Q2 2020.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.